首页 正文

Daratumumab Monotherapy versus Bortezomib-Based Regimens in frail patients with Biopsy-Proven Renal AL Amyloidosis

{{output}}
Background: Bortezomib-based regimens have long represented the standard option for systemic AL amyloidosis, whereas daratumumab has recently emerged as a promising alternative. We compared two consecutive single-center cohorts o... ...